This article is more than 5 years old. Information may no longer be current.
Top intervention news of February: DAPT duration, paclitaxel controversy updates and more
Cardiology Today’s Intervention and Healio Intervention compiled a list of the most-read intervention articles posted in February.
This month, our readers were interested in dual antiplatelet therapy duration after PCI, transcatheter aortic valve replacement in frail patients, updates on the controversy over a possible link between paclitaxel-coated devices and mortality, and more.
Long-term DAPT after PCI fails to benefit patients at high bleeding risk
Long-term dual antiplatelet therapy after PCI was not beneficial in patients at high bleeding risk, regardless of the complexity of their PCI, according to new data from the PRECISE-DAPT study.
TAVR, surgical AVR confer functional decline in older patients with frailty
Older patients with severe frailty who underwent transcatheter or surgical aortic valve replacement for aortic stenosis had an increased risk for functional decline or a lack of improvement after the procedure, according to a study published in JAMA Internal Medicine.
Apixaban plus aspirin may be beneficial after MitraClip implantation
Patients with maintained sinus rhythm experienced a lower adverse event rate with apixaban plus aspirin vs. single or dual antiplatelet therapy at 30 days after percutaneous repair of severe mitral regurgitation, according to a research letter published in JACC: Cardiovascular Interventions.
Antithrombotic therapy continues to evolve for patients with PAD
HOLLYWOOD, Fla. — Researchers continue to learn more about how best to treat patients with peripheral artery disease with antithrombotic therapies without increasing their risk for bleeding, according to a presentation at the International Symposium on Endovascular Therapy.
TAVR with transcarotid approach safe in patients with severe aortic stenosis
The use of a transcatheter heart valve in patients who underwent transcatheter aortic valve replacement with the transcarotid approach was safe and effective, according to a study published in JACC: Cardiovascular Interventions.
VIDEO: Deep dive into paclitaxel concerns continues
HOLLYWOOD, Fla. — In this video exclusive, William A. Gray, MD, presents his top highlights from the International Symposium on Endovascular Therapy, including a “robust and deep dive” into the recent controversy surrounding paclitaxel-coated devices.
No evidence of paclitaxel-related mortality risk in real-world PAD cohort
In a cohort of CMS beneficiaries with peripheral artery disease, there was no evidence that those revascularized with a drug-coated device had increased risk for mortality compared with those who were not, researchers reported in JAMA Cardiology.
VIDEO: ‘International crisis’ of PE at forefront of vascular intervention
In this video exclusive, Kenneth Rosenfield, MD, MHCDS, discusses recent advancements and ongoing challenges in addressing the “international crisis” of pulmonary embolism.
FDA approves ultrathin bioabsorbable coronary stent
Biotronik announced that a drug-eluting stent system for the treatment of patients with CAD has been approved by the FDA and is commercially available in the U.S.
IVC filter overuse declining, but retrieval rates remain low
HOLLYWOOD, Fla. — Overuse of inferior vena cava filters is not as much of a problem as it used to be, but inappropriate use still occurs and retrieval too often does not happen quickly enough, an expert said at the International Symposium on Endovascular Therapy.